The Neuroprotector's Dilemma: A Potential Neuroprotective Agent with a Janus Face

Posted by Michael Rae on October 01, 2014 | Chief Science Officer's Team

Rejuvenation of the aging brain will require the integrated application of several core rejuvenation biotechnologies, including notably those that remove intra- and extraneuronal aggregates implicated in neurodegenerative aging and mature cell therapy. Numerous aggregate-clearing rejuvenation biotechnologies are now in human trials, whereas mature cell therapy for the brain is a more challenging goal and will not be available for some time. In this context, an alternative approach to maintaining the viability of aging neurons could complement aggregate-clearing therapies to preserve neurons until neural replacement and reinforcement matures. In this post we explore the potential of one recently-emerged approach: inhibition of the unfolded protein response (UPR).

2013 Research Report (Part 7 of 12): Extracellular Aggregates

Posted by Iain Inkster on January 06, 2014 | SRF Research

University of Texas, Houston TX, and Brigham and Women’s Hospital, Harvard University, Boston MA Researchers: Sudhir Paul, Yasuhiro Nishiyama, Stephanie Planque (University of Texas); Brian O’Nuallain (Brigham and Women's Hospital, Harvard Medical School)

2013 Research Report (part 6 of 12): Epimutations

Posted by Iain Inkster on December 05, 2013 | SRF Research

Albert Einstein College of Medicine (AECOM), Bronx NY Researchers: Jan Vijg, Silvia Gravina

2013 Research Report (Part 5 of 12): Lysosomal Aggregates

Posted by Iain Inkster on November 08, 2013 | SRF Research

Researchers: Pedro Alvarez, Jacques Mathieu, Jason Gaspar

2013 Research Report (part 4 of 12): Extracellular Matrix Stiffening

Posted by Iain Inkster on November 01, 2013 | SRF Research

Our arteries slowly stiffen with age, in substantial part because of chemical crosslinking of their structural proteins by blood sugar and other fuels in the circulation. Like the crosslinking that causes rubber windshield wipers to become stiff and brittle over time, the crosslinking of arterial proteins with age leaves us with increasingly rigid blood vessels...

2013 Research Report (part 3 of 12): Cancerous Cells

Posted by Iain Inkster on October 18, 2013 | SRF Research

Researchers: Haroldo Silva, David Halvorsen, Kelsey Moody, Thomas Hunt

2013 Research Report (part 2 of 12): Mitochondrial Mutations

Posted by Iain Inkster on October 09, 2013 | SRF Research

Researchers: Matthew O'Connor, Amutha Boominathan, Jayanthi Vengalam

Unbinding the Mummies: Human Testing of Rejuvenation Biotechnology Targeting α-Synuclein Begins

Posted by Michael Rae on October 02, 2013 | Chief Science Officer's Team

Aggregates of the neuronal membrane protein α-synuclein accumulate in the aging brain and are implicated in the non-motor symptoms of Parkinson's disease and related disorders, as well as subtler age-related dysfunction of the autonomic and peripheral nervous system. Preclinical evidence demonstrates that immunotherapeutic clearance of these aggregates in transgenic animals rescues Parkinson's-like behavioral and cognitive dysfunction. With support from a major Parkinson's research and advocacy charity, an Austrian biotech firm has advanced a first-in-class rejuvenation biotechnology targeting α-synuclein aggregates into Phase I clinical trials.

2013 Research Report (part 1 of 12): Lysosomal Aggregates

Posted by Iain Inkster on September 01, 2013 | SRF Research

Researchers: Gouri Yogalingam, Ghezal Beliakoff, Ehud Goldin, Maximus Peto

New and Better Clinical Trials for Rejuvenation Biotechnologies

Posted by Michael Rae on July 31, 2013 | Chief Science Officer's Team

The need for disease-modifying therapies in Alzheimer's disease, and the strength of the case for aggregated beta-amyloid as a target, have recently driven substantial regulatory reform and innovations in clinical trial design to open up the path for faster and more effective human testing and approval of novel Alzheimer's therapeutics. The first fruits of these changes are a series of large, late-stage clinical trials of immunotherapies targeting the removal of beta-amyloid from the brain. These reforms and precedents open up the path for human testing and approval of future rejuvenation biotechnologies.

Amutha Boominathan: Moving vulnerable mitochondrial genes to the safety of the nucleus

Posted by iain.inkster on July 24, 2013 | SRF Research

We all know that mitochondria are the cell's "powerhouse" for energy. One interesting fact about these organelles is that they have their own DNA in addition to the nuclear DNA that we are all aware of. However, the mitochondrial DNA is prone to mutations due to constant exposure from reactive oxygen species because it is not encased in a nuclear envelope nor does it have efficient repair mechanisms to correct mutations as they occur. Amutha Boominathan explains how moving the mitochondrial genes to the nucleus, where it's safer to express them for function, would let mitochondria keep producing energy normally, even after mitochondrial mutations have occurred.

Jayanthi Vengalam: Engineering backup mitochondrial genes

Posted by iain.inkster on July 20, 2013 | SRF Research

Jayanthi Vengalam explains her work with the Mitochondrial Mutation team, with consequences for acute diseases such as diabetes, Parkinson's and Alzheimer's